You know my favourite MS drug…yep you guessed it,…..it’s glatiramer acetate. This has been doing the rounds since the 1970s and was the World’s favourite MS drug. I have to say that as an EAEer I have struggled to get it to do much, except in one certain way, hence my tounge in cheek reports. I obviously don’t have the green fingers of some of my colleagues. Perhaps that’s why I don’t believe anything that comes out of their lab:-(
However, this post is genius, as it has ProfG and K sandwiched at both ends of the paper, so they know I won’t comment on this .
As you all know the Risk Sharing Scheme was a bit of a con to allow you to get access to drugs that the powers that be didn’t think were very good. So the RSS allowed access to drugs at reduced cost with the proviso that if they were found to be cost-effective could charge more, they were found cost effectivie and guess what? They charged more. Now I will let ProfG and K sing the virtue of this report. The cat has got my tonugue
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme. Giovannoni G, Brex PA, Dhiraj D, Fullarton J, Freddi M, Rodgers-Gray B, Schmierer K. Mult Scler J Exp Transl Clin. 2019 Dec 5;5(4):2055217319893103. doi: 10.1177/2055217319893103. eCollection 2019 Oct-Dec
BACKGROUND: The UK Risk Sharing Scheme (RSS) provided information on the effect of first-line multiple sclerosis (MS) disease-modifying treatments on long-term disability.
OBJECTIVE: The aim is to provide results specific to glatiramer acetate (GA; Copaxone®) from the final 10-year analysis of the RSS.
METHODS: A Markov model was used to assess clinical effectiveness measured as Expanded Disability Status Scale (EDSS) progression and utility loss. Untreated patients from the British Columbia MS cohort (1980-1995) were used as a ‘virtual comparator’ group. A separate Markov model assessed cost-effectiveness, based on a 50-year time horizon (with a 50% treatment waning effect imposed at 10 years) and using NHS list price (£513.95 per 28 days). Results were expressed in quality-adjusted life years (QALYs).
RESULTS: In total, 755 patients with relapsing-remitting MS (RRMS) received GA, with a mean follow-up of 7.1 (standard deviation 1.3) years. EDSS progression was reduced by 23% (progression ratio 76.7, 95% confidence interval [CI] 69.0-84.3) and utility loss by 39% (progression ratio 61.0, 95% CI 52.7-69.3) compared with no treatment. There was no persistent waning in GA treatment effect over time (EDSS: p = 0.093; utilities: p = 0.119). The cost per QALY was £17,841.
CONCLUSION: GA had a beneficial effect on long-term disability and was a cost-effective treatment for RRMS.